|apersy|

Value | Market Access | Commercialisation

Tag: JCA

  • Starting 2025: Don’t forget to look beyond the JCA

    Starting 2025: Don’t forget to look beyond the JCA

    While we are certainly all on lookout for the first EU Joint Clinical Assessments (JCA), there are quite a few other access, financing, pricing and reimbursement news and changes to watch as 2025 starts…

  • Uncertainties Surrounding the EU Joint Clinical Assessment: What do biotechs need to monitor

    Uncertainties Surrounding the EU Joint Clinical Assessment: What do biotechs need to monitor

    With the implementation of the new EU Health Technology Assessment (HTA) Regulation just four months away, uncertainties remain. The most important ones we will look at in this short clip, before exploring strategies for success the next time.

  • Nononsense EU JCA

    Nononsense EU JCA

    No-nonsense EU HTA Introducing bit-sized no-nonsense insights about the EU HTA Regulation, Joint Clinical Assessment, Joint Scientific Consultations, etc etc. In a series of posts, there will be Q&A, process overviews, insights about preparedness, uncertainties and unknowns, as well as news as they happen in the continuing implementation phase. Got a question or query to…